Takeda's maribavir clears cytomegalovirus infections in phase 3

Takeda has shared results from a successful phase 3 clinical trial of maribavir in transplant recipients with refractory cytomegalovirus (CMV) infection. The trial suggests maribavir is better at clearing the virus from the blood than existing treatments such as ganciclovir and valganciclovir.